"Sanofi-Aventis (SNY), a pharmaceutical products company, is a buy based on our 'Benjamin Graham value' model," says John Reese who assesses stocks based on the investment criteria of numerous "legendary" investors.

The editor of Validea, explains, "Indeed, the stock earns a 100% score, meeting all of the investment criteria we review in for this value-oriented screen.

Continue reading Sanofi-Aventis (SNY): 100% Score on a Ben Graham Value Model

Sanofi-Aventis (SNY): 100% Score on a Ben Graham Value Model originally appeared on BloggingStocks on Fri, 01 Apr 2011 12:00:00 EST. Please see our terms for use of feeds.

"After releasing their 3Q financials. the stock price at Isis Pharmacueticals (ISIS) perked up as their large cash position and deep pipeline have attracted some new investors," notes biotech expert John McCamant.

The editor of The Medical Technology Stock Letter explains, "When investors investigate the ISIS story and all its parts, they come away with an appreciation for all the potential long-term value being created at the company.

Continue reading Isis (ISIS): 'Deep Pipeline, Long-Term Value'

Isis (ISIS): 'Deep Pipeline, Long-Term Value' originally appeared on BloggingStocks on Fri, 17 Dec 2010 13:00:00 EST. Please see our terms for use of feeds.

The editor of Dow Theory Forecasts explains, "One exception is Abbott Laboratories (ABT); Wall Street expects to increase earnings at a 10% annual rate over the next five years.

"Yet the market appears to discount that outlook, and the stock's price/earnings-to-growth ratio (PEG) of 1.2 is well below its peers.

Continue reading Abbott Labs (ABT): A Rich Pipeline in Pharma

Abbott Labs (ABT): A Rich Pipeline in Pharma originally appeared on BloggingStocks on Wed, 01 Dec 2010 10:20:00 EST. Please see our terms for use of feeds.

"Johnson & Johnson (JNJ) is an international giant, employing more than 115,000 people and operating in 60 countries," notes Gavin Graham.

The contributing analyst to Internet Wealth Builder explains, "The conservative stock is in a great business in an almost recession-proof field. Indeed, we see this an opportunity to buy a world-class stock at a reasonable price.

"It is a major provider of prescription drugs, including Remicade for arthritis and Procrit for red blood cell production.

Continue reading Johnson & Johnson (JNJ): World Class Buy

Johnson & Johnson (JNJ): World Class Buy originally appeared on BloggingStocks on Tue, 09 Nov 2010 10:30:00 EST. Please see our terms for use of feeds.

The editor of Validea continues, "Sanofi-Aventis (SNY), which is involved in pharmaceuticals and human vaccines, earns a Guru Score of 100% based on the value investing strategy of Benjamin Graham.

"In its pharmaceutical activity, the company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system (CNS), and internal medicine.

Continue reading Sanofi-Aventis (SNY): A Ben Graham Value Buy

Sanofi-Aventis (SNY): A Ben Graham Value Buy originally appeared on BloggingStocks on Mon, 25 Oct 2010 11:00:00 EST. Please see our terms for use of feeds.

The editor of Cabot Benjamin Graham Value Letter explains, "Gilead is a biopharmaceutical company that discovers, develops and markets therapeutic treatments to combat viral, bacterial and fungal infections. Its shares undervalued at 9.7 times forward 12-month EPS.

"Teva, based in Israel, develops, makes and sells generic and proprietary-branded (store brand) drugs. Its shares are clearly undervalued at 10.6 times forward EPS. We consider both stocks to be very low risk.

Continue reading Ben Graham Buys in Pharma: Gilead (GILD) and Teva (TEVA)

Ben Graham Buys in Pharma: Gilead (GILD) and Teva (TEVA) originally appeared on BloggingStocks on Thu, 14 Oct 2010 11:00:00 EST. Please see our terms for use of feeds.

"Foreign corporations have been on a mini buying spree in 2010. Not surprising, merger and acquisition activity has heated up a bit in the drug sector," says Chuck Carlson, editor of The DRIP Investor.

The dividend expert explains, " Global merger and acquisition activity topped $1 trillion in the first half of 2010, a 9.4% increase over the previous year. And Bristol-Myers Squibb (BMY), recommend stock in our Editor's Portfolio, has been one of the more active participants.

Continue reading Bristol-Myers Squibb (BMY): Buying Growth?

Bristol-Myers Squibb (BMY): Buying Growth? originally appeared on BloggingStocks on Wed, 29 Sep 2010 13:00:00 EST. Please see our terms for use of feeds.

"For years the health care sector had a well-deserved reputation for consistent returns and profitability regardless of broader economic conditions," observes Elliott Gue.

The contributing editor to Personal Finance explains, "But the past two years have challenged this reputation, and these stocks are out of favor. Some favorites, such as Novartis (NVS) are trading at their most attractive valuation in years.

"Although the sector faces undeniable challenges, markets often overreact to new regulation, providing attractive entry points for savvy investors and a low bar of expectations.

Continue reading Novartis (NVS): Pharma Favorite with Solid Pipeline

Novartis (NVS): Pharma Favorite with Solid Pipeline originally appeared on BloggingStocks on Thu, 26 Aug 2010 13:00:00 EST. Please see our terms for use of feeds.

"New products are the life-blood of any pharmaceutical company. Unfortunately, blockbuster drug breakthroughs have been fairly rare in recent years, lowering valuations for pharmaceutical stocks," says Chuck Carlson.

The editor of The DRIP Investor, which focuses on dividend reinvestment strategies, explains, "The good news is that the lone drug stock in the Editor's Portfolio, Bristol-Myers Squibb (BMY), has had a spate of good news recently on the drug-development front.

"The company recently announced that a mid-stage trial of an experimental arthritis drug had met its goal, supporting further development of the drug.

Continue reading Bristol-Myers Squibb (BMY): 'Solid, Quality Play'

Bristol-Myers Squibb (BMY): 'Solid, Quality Play' originally appeared on BloggingStocks on Mon, 26 Jul 2010 10:00:00 EST. Please see our terms for use of feeds.

"Sanofi-Aventis (SNY) is a pharmaceutical group engaged in the research, development, manufacture and marketing of health care products; the stock gets a 100% score in meeting the criteria for our investment screen based on d value investing criteria used by the legendary Benjamin Graham," says John Reese.

The editor of Validea newsletter explains, "The company's business includes two main activities: pharmaceuticals and human vaccines. The company is also present in animal health products.

"In its pharmaceutical activity, the Company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system), and internal medicine.

Continue reading Sanofi-Aventis (SNY): A Ben Graham Value Buy

Sanofi-Aventis (SNY): A Ben Graham Value Buy originally appeared on BloggingStocks on Wed, 30 Jun 2010 10:15:00 EST. Please see our terms for use of feeds.

Continue reading Johnson & Johnson (JNJ) : 'Dirt Cheap Valuation'

Johnson & Johnson (JNJ) : 'Dirt Cheap Valuation' originally appeared on BloggingStocks on Tue, 29 Jun 2010 10:00:00 EST. Please see our terms for use of feeds.

Continue reading Sanofi-Aventis (SNY): A Growth and Value Play

Sanofi-Aventis (SNY): A Growth and Value Play originally appeared on BloggingStocks on Mon, 05 Apr 2010 12:00:00 EST. Please see our terms for use of feeds.

A lot of investors think Amgen (AMGN) is a great next-generation biotech company. Wrong. Amgen was a decent last-generation biotech company.

It's terribly managed outfit living on EPO drugs for dialysis and oncology patients. True, it has a billion dollar (actually more) drug, Neupogen, but it could be subject to generic competition in the United States from TEVA within two years.

Continue reading Deadbeat Stock #6: Amgen (AMGN)

Deadbeat Stock #6: Amgen (AMGN) originally appeared on BloggingStocks on Sun, 21 Mar 2010 13:00:00 EST. Please see our terms for use of feeds.

This declining company lost patent protection for its statin, Zocor. It has replaced some of these sales with three new drugs, but, in reality, they cannot make up for the lost revenue from Zocor.

Merck's (MRK) revenues are stagnant and the company has a very weak pipeline. Even if health care reform adds more patients, it will also bring increased pressure to cut prices.

Continue reading Deadbeat Stock #5: Merck (MRK)

Deadbeat Stock #5: Merck (MRK) originally appeared on BloggingStocks on Sun, 21 Mar 2010 11:00:00 EST. Please see our terms for use of feeds.

Pfizer (PFE) was the darling of the 1990s. Well, so was Bill Clinton, and like Clinton, the company pops up now and again in the news, but none of it really matters.

Pfizer's premier product, Lipitor, comes off patent this year and will get hit by generic competition in 2011. This drug has $11 billion in sales, which will shrink to $4 billion or less, and with that could go $5 billion or so in profits.

Continue reading Deadbeat Stock #4: Pfizer (PFE)

Deadbeat Stock #4: Pfizer (PFE) originally appeared on BloggingStocks on Sun, 21 Mar 2010 09:00:00 EST. Please see our terms for use of feeds.

Spring is finally here, which means it's time to break out the broom and dustpan for some spring cleaning.

But your home isn't the only thing that requires constant maintenance -- your portfolio does too.

And what better time than spring to get a fresh start by cleaning out the stocks that are sitting around collecting dust rather than making you money?

Continue reading Six Deadbeat Stocks to Clean Out of Your Portfolio

Six Deadbeat Stocks to Clean Out of Your Portfolio originally appeared on BloggingStocks on Sat, 20 Mar 2010 09:00:00 EST. Please see our terms for use of feeds.

"It's time for income investors to come back to what's historically been a mainstay of diversified portfolios: big pharmaceutical companies. We're adding one of the sector's most durable members to the Income Portfolio, Bristol-Myers Squibb (BMY)," says Roger Conrad.

In Personal Finance newsletter, he explains, "The stock has been a lackluster performer since the 1990s, when it was last a Portfolio recommendation. The company's underlying business, however, has become ever-more valuable.

Continue reading Bristol-Myers Squibb (BMY): Time to Buy Pharma

Bristol-Myers Squibb (BMY): Time to Buy Pharma originally appeared on BloggingStocks on Thu, 25 Feb 2010 11:00:00 EST. Please see our terms for use of feeds.

"Stocks are likely in a new downtrend," says Michael Ashbaugh. In Marketwatch's The Technical Indicator, he looks at the S&P's prospects and some drug stocks set to buck the trend.

"The S&P 500 has violated its major moving averages in the closely tracked 900 area. The recent downturn was convincingly bearish, placing the burden on market bulls to reassert the uptrend.

"After finding resistance in the 923 area, the S&P sold off sharply, edging back under its 200-day moving average, which currently holds at 900 and now marks resistance. This is bearish price action.

Continue reading Tech talk from MarketWatch

Tech talk from MarketWatch originally appeared on BloggingStocks on Thu, 25 Jun 2009 11:00:00 EST. Please see our terms for use of feeds.

"Few industries seem as well positioned for future growth as the generic drug industry," says small-cap growth stock specialist Tom Bishop.

In his BI Research newsletter, he explains, "With demographic pointing to an increasingly aging population, and healthcare costs spiraling out of control, low cost generic drugs are clearly part of the solution." Here's a look at generic drug maker Mylan (NYSE: MYL).

"High on the agenda of the Obama administration is to bring health care coverage to some 40 million Americans who are currently not covered.

Continue reading Generic gains from Mylan (MYL)

Generic gains from Mylan (MYL) originally appeared on BloggingStocks on Mon, 18 May 2009 12:30:00 EST. Please see our terms for use of feeds.

In a review of the pharmaceutical sector, Chuck Carlson selects his favorite International stocks which also offer direct-purchase plans for U.S. investors.

Here's a look at two of these stocks -- United Kingdom-based AstraZeneca (NYSE: AZN) and Denmark-based Novo Nordisk (NYSE: NVO) -- from his The DRIP Investor, a newsletter focused on long-term, high quality investments.

"AstraZeneca is a leading pharmaceutical firm. The company boasts a portfolio that includes 11 products that generate more than $1 billion each in annual sales.

Continue reading Global pharma favorites

Global pharma favorites originally appeared on BloggingStocks on Thu, 14 May 2009 13:30:00 EST. Please see our terms for use of feeds.